Literature DB >> 7538264

Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

H F Dvorak1, L F Brown, M Detmar, A M Dvorak.   

Abstract

VPF/VEGF is a multifunctional cytokine that contributes to angiogenesis by both direct and indirect mechanisms. On the one hand, VPF/VEGF stimulates the ECs lining nearby microvessels to proliferate, to migrate, and to alter their pattern of gene expression. On the other hand, VPF/VEGF renders these same microvascular ECs hyperpermeable so that they spill plasma proteins into the extravascular space, leading to the clotting of extravasated fibrinogen with deposition of a fibrin gel. Extravascular fibrin serves as a provisional matrix that favors and supports the ingrowth of new blood vessels and other mesenchymal cells that generate mature, vascularized stroma. These same principles apply in tumors, in several examples of non-neoplastic pathology, and in physiological processes that involve angiogenesis and new stroma generation. In all of these examples, microvascular hyperpermeability and the introduction of a provisional, plasma-derived matrix precede and accompany the onset of EC division and new blood vessel formation. It would seem, therefore, that tumors have "borrowed" fundamental mechanisms that developed in multicellular organisms for purposes of tissue defense, renewal, and repair. VPF/VEGF, therefore has taught us something new about angiogenesis; namely, that vascular hyperpermeability and consequent plasma protein extravasation are important, perhaps essential, elements in its generation. However, this finding raises a paradox. While VPF/VEGF induces vascular hyperpermeability, other potent angiogenic factors apparently do not, at least in subtoxic concentrations that are more than sufficient to induce angiogenesis. Nonetheless, wherever angiogenesis has been studied, the newly generated vessels have been found to be hyperpermeable. How, therefore, do angiogenic factors other than VPF/VEGF lead to the formation of new and leaky blood vessels? We do not as yet have a complete answer to this question. One possibility is that at least some angiogenic factors mediate their effect by inducing or stimulating the expression of VPF/VEGF. In fact, there is already one clear example of this. TGF-alpha is a potent angiogenic factor but does not itself increase microvascular permeability. However, TGF-alpha strikingly upregulates VPF/VEGF expression in cultured keratinocytes and is thought to be responsible, at least in part, for the overexpression of VPF/VEGF in psoriasis. Moreover, overexpression of TGF-alpha, along with that of the EGF receptor with which it interacts, is characteristic of many malignant tumors, raising the possibility that TGF-alpha acts to stimulate VPF/VEGF expression in other types of epithelial cells and in this manner induces angiogenesis.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538264      PMCID: PMC1869291     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  110 in total

1.  Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line.

Authors:  G Conn; D D Soderman; M T Schaeffer; M Wile; V B Hatcher; K A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

2.  Vascular endothelial growth factor is expressed in rat corpus luteum.

Authors:  H S Phillips; J Hains; D W Leung; N Ferrara
Journal:  Endocrinology       Date:  1990-08       Impact factor: 4.736

3.  Characterization of the receptors for vascular endothelial growth factor.

Authors:  N Vaisman; D Gospodarowicz; G Neufeld
Journal:  J Biol Chem       Date:  1990-11-15       Impact factor: 5.157

4.  Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology.

Authors:  D Parent; B A Bernard; C Desbas; M Heenen; M Y Darmon
Journal:  J Invest Dermatol       Date:  1990-09       Impact factor: 8.551

5.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

Authors:  E Tischer; R Mitchell; T Hartman; M Silva; D Gospodarowicz; J C Fiddes; J A Abraham
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

6.  Alterations in proteoglycan synthesis common to healing wounds and tumors.

Authors:  T K Yeo; L Brown; H F Dvorak
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

7.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

Authors:  D R Senger; D T Connolly; L Van de Water; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

8.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

9.  Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells.

Authors:  T A Brock; H F Dvorak; D R Senger
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

10.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration.

Authors:  M Clauss; M Gerlach; H Gerlach; J Brett; F Wang; P C Familletti; Y C Pan; J V Olander; D T Connolly; D Stern
Journal:  J Exp Med       Date:  1990-12-01       Impact factor: 14.307

View more
  665 in total

1.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery.

Authors:  C Sundberg; J A Nagy; L F Brown; D Feng; I A Eckelhoefer; E J Manseau; A M Dvorak; H F Dvorak
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

2.  Reversal of experimental diabetic neuropathy by VEGF gene transfer.

Authors:  P Schratzberger; D H Walter; K Rittig; F H Bahlmann; R Pola; C Curry; M Silver; J G Krainin; D H Weinberg; A H Ropper; J M Isner
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways.

Authors:  D O Bates; R I Heald; F E Curry; B Williams
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

4.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

5.  In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice.

Authors:  C J Bruns; M T Harbison; H Kuniyasu; I Eue; I J Fidler
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

6.  Heparin-binding ligands mediate autocrine epidermal growth factor receptor activation In skin organ culture.

Authors:  S Stoll; W Garner; J Elder
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 7.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

8.  Vascular endothelial growth factor gene polymorphism and acute respiratory distress syndrome.

Authors:  A R L Medford; L J Keen; J L Bidwell; A B Millar
Journal:  Thorax       Date:  2005-03       Impact factor: 9.139

9.  VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population.

Authors:  Melissa D Amosco; Van Anthony M Villar; Justin Michael A Naniong; Lara Marie G David-Bustamante; Pedro A Jose; Cynthia P Palmes-Saloma
Journal:  Clin Exp Hypertens       Date:  2016-09-26       Impact factor: 1.749

10.  Blood-spinal cord barrier after spinal cord injury: relation to revascularization and wound healing.

Authors:  William D Whetstone; Jung-Yu C Hsu; Manuel Eisenberg; Zena Werb; Linda J Noble-Haeusslein
Journal:  J Neurosci Res       Date:  2003-10-15       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.